Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

CD44 in colon cancer

P Herrlich1, S Pals, H Ponta

  • 1Forschungszentrum Karlsruhe, Institut für Genetik, Germany.

European Journal of Cancer (Oxford, England : 1990)
|July 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tuberculosis preventive treatment opportunities at antiretroviral therapy initiation and follow-up visits.

Public health action·2020
Same author

Improving sputum collection processes to increase tuberculosis case finding among HIV-positive persons in Botswana.

Public health action·2020
Same author

Assessment of routine screening of pediatric contacts of adults with tuberculosis disease in Tanzania.

Public health action·2020
Same author

Delay in the Provision of Antiretroviral Therapy to HIV-infected TB Patients in Nigeria.

Universal journal of public health·2018
Same author

Epidermal-specific deletion of CD44 reveals a function in keratinocytes in response to mechanical stress.

Cell death & disease·2016
Same author

Perspectives of CD44 targeting therapies.

Archives of toxicology·2014
Same journal

Mismatch repair deficiency or microsatellite instability in locally advanced rectal cancer patients treated with total neoadjuvant therapy.

European journal of cancer (Oxford, England : 1990)·2026
Same journal

Phase I/Ib study evaluating safety, efficacy, pharmacokinetics and pharmacodynamics of NIZ985 monotherapy and in combination with an anti-PD-1 agent in patients with advanced solid tumors or lymphoma.

European journal of cancer (Oxford, England : 1990)·2026
Same journal

Early-onset colorectal cancer across Europe: Burden, mechanisms, and health-system implications.

European journal of cancer (Oxford, England : 1990)·2026
Same journal

Clinical urgency of incidental findings in the first year of the 4-IN-THE-LUNG-RUN lung cancer screening program.

European journal of cancer (Oxford, England : 1990)·2026
Same journal

Clinically relevant endpoints and quality-of-life outcomes with darolutamide in patients with metastatic hormone-sensitive prostate cancer: Analyses of the phase III ARASENS trial.

European journal of cancer (Oxford, England : 1990)·2026
Same journal

Mapping the anatomical landscape of colorectal tumours: Location-specific efficacy of anti-epidermal growth factor receptor antibodies: Pooled analysis of randomised trials.

European journal of cancer (Oxford, England : 1990)·2026
See all related articles

CD44 splice variants are crucial in cancer progression and metastasis. Specific variants, like CD44 exon v6, are linked to poor prognosis in breast cancer and colorectal tumors, suggesting a role in tumor cell advantage.

Area of Science:

  • Molecular biology
  • Cancer research
  • Immunology

Background:

  • Alternative splicing of CD44 (Cluster of Differentiation 44) gene generates numerous protein isoforms.
  • CD44 splice variants are implicated in tumor progression and metastasis.
  • Specific variants, such as CD44 exon v6, are associated with poor patient prognosis in certain cancers.

Purpose of the Study:

  • To investigate the role of CD44 splice variants in cancer development and metastasis.
  • To correlate the expression of specific CD44 variants (v5 and v6) with tumor progression and patient survival in colorectal cancer.
  • To explore the potential impact of CD44 isoforms on immune response.

Main Methods:

  • Analysis of CD44 alternative splicing and variant exon expression in tumor samples.

Related Experiment Videos

  • Correlation studies between CD44 variant expression and clinicopathological features (tumor stage, survival).
  • Use of transgenic mouse models to study the functional effects of CD44 isoforms on immune responses.

    • Main Results:

    • CD44 exon v5 is an early marker in colorectal carcinogenesis.
    • CD44 exon v6 expression increases with tumor progression and correlates with reduced survival in colorectal cancer.
    • CD44 exon v6 expression is linked to poor prognosis in breast cancer and non-Hodgkin's lymphomas.
    • Mice expressing CD44v4-v7 isoforms exhibit an accelerated T-dependent immune response.

    Conclusions:

    • CD44 splice variants play significant roles in tumor progression and metastasis.
    • CD44 exon v6 may confer a selective advantage to tumor cells, potentially through enhanced proliferation and immune response modulation.
    • Targeting specific CD44 variants could offer therapeutic strategies for cancer treatment.